Skip to main content
Lasa Supergenerics Limited logo

Lasa Supergenerics Limited — Investor Relations & Filings

Ticker · LASA ISIN · INE670X01014 LEI · 984500B9EA5EC3R2F726 BSE.NS Manufacturing
Open in API
Filings indexed 453 across all filing types
Latest filing 2026-05-19 Regulatory Filings
Country IN India
Listing BSE.NS LASA

About Lasa Supergenerics Limited

https://lasalabs.com/

Lasa Supergenerics Limited is a vertically integrated manufacturer specializing in Active Pharmaceutical Ingredients (APIs) for both veterinary and human health applications. The company focuses on the research, development, and production of high-quality chemical intermediates and APIs. Its core product portfolio includes a significant range of anthelmintics, such as Albendazole, Fenbendazole, and Ricobendazole, alongside other specialized therapeutic categories. Utilizing advanced manufacturing facilities and a dedicated research and development wing, the organization emphasizes cost-effective production processes and stringent quality control standards. Lasa Supergenerics Limited serves a global clientele, providing essential components for pharmaceutical formulations and animal health products through its expertise in complex chemical synthesis and large-scale manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve Pursuant to Regulation 29 ....
Regulatory Filings Classification · 75% confidence The document is a formal notice to stock exchanges under SEBI Listing Regulations informing about a Board meeting date to consider and approve audited financial results. It does not contain the actual results nor detail a management change, but is a regulatory announcement. This fits the generic “Regulatory Filings” category rather than a financial report or management change filing.
2026-05-19 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 87% confidence The document is a compliance certificate under SEBI (Depositories and Participants) Regulations 2018, providing an officer attestation about dematerialization of shares, with no substantive financial data or management discussion. It is a regulatory certification filed with stock exchanges. Per the CERTIFICATION RULE, such an attestation letter is classified as a regulatory filing (RNS) rather than a financial report type.
2026-05-12 English
Certificate Reg 74 (5) of SEBI (DP) Regulations , 2018 as on 31st March 2026
Regulatory Filings Classification · 98% confidence The document is a compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, submitted by the Registrar and Share Transfer Agent to the stock exchanges for the quarter and year ended March 31, 2026. It is an attestation letter rather than a financial report, earnings release, or AGM material. Per the Certification Rule and because it does not contain substantive financial data itself but is an officer/regulatory attestation, it should be classified as a general regulatory filing (RNS).
2026-05-12 English
Structural Digital Database
Regulatory Filings Classification · 95% confidence The document is a compliance certificate related to the Structured Digital Database (SDD) pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015. It certifies compliance for the quarter ended March 31, 2026. The document is a formal attestation by the Compliance Officer and does not contain financial statements or detailed financial data. It is primarily a regulatory compliance certification rather than a financial report or announcement of financial results. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for compliance certificates and regulatory attestations that do not fit other specific categories.
2026-04-16 English
Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the non-applicability of the Large Entities framework pursuant to a SEBI circular related to fund raising by issuance of debt securities. It is a regulatory compliance declaration rather than a financial report or announcement of financial results. The document is short (1193 characters) and serves as a formal notification to the exchanges. It does not contain financial data, audit information, management changes, or voting results. It fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance document.
2026-04-16 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges informing about the closure of the trading window for insiders due to the upcoming declaration of audited financial results for the quarter and year ended March 31, 2026. It references insider trading regulations and trading restrictions but does not contain any financial data, results, or detailed report content. The document is short (1630 characters) and serves as an announcement related to compliance and trading restrictions rather than a financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS) as a compliance-related announcement.
2026-03-30 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.